# A Trial for Patients With Advanced/Recurrent Cervical Cancer

> **NCT00190983** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 29 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia
- Uterine Neoplasms
- Genital Neoplasms, Female

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00190983
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2009-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190983, "A Trial for Patients With Advanced/Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00190983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*